Multicenter Phase II Study of MK-2206 in Previously Treated Patients With Recurrent and Metastatic Nasopharyngeal Carcinoma.

Trial Profile

Multicenter Phase II Study of MK-2206 in Previously Treated Patients With Recurrent and Metastatic Nasopharyngeal Carcinoma.

Discontinued
Phase of Trial: Phase II

Latest Information Update: 18 Jan 2017

At a glance

  • Drugs MK 2206 (Primary)
  • Indications Nasopharyngeal cancer
  • Focus Therapeutic Use
  • Most Recent Events

    • 28 Jan 2016 Planned End Date changed from 1 May 2015 to 1 Dec 2016 as per ClinicalTrials.gov record.
    • 28 Jan 2016 Planned primary completion date changed from 1 May 2015 to 1 Dec 2016 as per ClinicalTrials.gov record.
    • 21 May 2014 Planned End Date changed from 1 May 2014 to 1 May 2015 as reported by ClinicalTrials.gov record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top